DSpace Collection:https://hdl.handle.net/10171/522402024-03-29T08:13:05Z2024-03-29T08:13:05ZCorrection: Ordoñez, et al.; DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters? Cancers 2019, 11, 1424https://hdl.handle.net/10171/679562024-01-24T09:29:40Z2020-01-01T00:00:00ZTitle: Correction: Ordoñez, et al.; DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters? Cancers 2019, 11, 1424
Abstract: The authors would like to make a correction to their published paper2020-01-01T00:00:00ZMultiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityhttps://hdl.handle.net/10171/671642024-01-29T07:56:35Z2020-01-01T00:00:00ZTitle: Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Abstract: There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19.2020-01-01T00:00:00ZMolecular profiling of immunoglobulin heavychain gene rearrangements unveils new potential prognostic markers for multiple myeloma patientshttps://hdl.handle.net/10171/671562024-01-29T07:56:35Z2020-01-01T00:00:00ZTitle: Molecular profiling of immunoglobulin heavychain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Abstract: Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although
B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain
features in the outcome has not been extensively explored. Here we present the characterization of complete heavychain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by
next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with
significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in
our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high
hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features
and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival
rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall
survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new
insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these
clonal rearrangement characteristics as new potential prognostic markers.2020-01-01T00:00:00ZInternational Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)https://hdl.handle.net/10171/666942023-10-26T07:28:03Z2020-01-01T00:00:00ZTitle: International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM
was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition
of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to
develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable
analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR:
2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This
translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for
intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2–3 factors). Addition of cytogenetic abnormalities
(t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1,
intermediate risk with 2, and high risk with ≥3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years,
respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical
research and routine practice and will be widely applicable.2020-01-01T00:00:00Z